HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Shih, T. T.-F. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Shih, T. T.-F. Social Bookmarking                      What's this?

Dynamic Contrast-Enhanced MRI Analysis of Perfusion Changes in Advanced Hepatocellular Carcinoma Treated with an Antiangiogenic Agent: A Preliminary Study

¹ Department of Medical Imaging, National Taiwan University Hospital and Department of Radiology, National Taiwan University College of Medicine, No. 7, Chung-Shan S Rd., Taipei 100, Taiwan.
² Division of Cancer Research, National Health Research Institute, Taipei, Taiwan.
³ Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

Abstract

OBJECTIVE. To evaluate the perfusion changes in advanced hepatocellular carcinoma (HCC) treated with the antiangiogenic agent thalidomide, we used dynamic contrast-enhanced MRI.

SUBJECTS AND METHODS. Dynamic contrast-enhanced MRI was performed before and during thalidomide treatment in seven patients with advanced unresectable HCC that had failed to respond to prior local therapy. A turbo fast low-angle shot sequence was performed in a 1.5-T MR scanner. An operator-defined region of interest was placed in the maximal enhancement region of the tumor site and adjacent tumor-free parenchyma of all patients. A time–intensity curve was plotted and analyzed. The peak enhancement in the first-pass study, the maximal enhancement, and the initial enhancement slope percentage in the first-pass study of the tumor and parenchyma were measured. The changes in these three perfusion parameters were estimated and correlated with clinical outcomes. The seven patients were categorized into two groups on the basis of their clinical outcomes: group A patients were those who had progressive disease, whereas group B patients were those who had stable disease or partial response.

RESULTS. Four of the seven patients were classified as group A, and the other three were classified as group B patients. When comparing the MRI parameters for the tumors before and during treatment in group A and group B patients, we found a statistically significant difference for the peak enhancement in the first-pass study, the maximal enhancement, and the enhancement slope percentage in the first-pass study. When comparing the parenchymal parameters, we found a statistically significant difference in the maximal enhancement and borderline significance in the peak enhancement in the first-pass study (p = 0.057) between group A and group B patients.

CONCLUSION. The dynamic MRI parameters showed significant differences between two groups of patients with different clinical outcomes.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?